Risk of infection with PPI therapy

Gastroenterology and Hepatology

Volumn 7, Issue 4, 2011, Pages 10-12

  Vaezi, Michael F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE;

AGED; ARTICLE; ATTITUDE TO ILLNESS; BACTERIAL OVERGROWTH; CAMPYLOBACTER; CAMPYLOBACTERIOSIS; CASE REPORT; CELL ADHESION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; ENDOTHELIUM CELL; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HUMAN; INFECTION RISK; INTESTINE INFECTION; LEUKOCYTE; META ANALYSIS (TOPIC); PATIENT ATTITUDE; PHAGOCYTOSIS; PNEUMONIA; SALMONELLA; SALMONELLOSIS; STOMACH ACID SECRETION;

EID: 79955752209     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxbock F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30:1118-1122. (Pubitemid 34508037)
2. Yoshida N, Yoshikawa T. Tanaka Y, et al. A new mechanism for atii-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(suppl 1):74-81. (Pubitemid 30199109)
3. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 2010;8:504-508.
4. Gray JA, Trueman AM. Severe salmonella gastroenteritis associated with hypochlorhydria. Scott Med J. 1971;16:255-258.
5. Dial MS. Proton pump inhibitor use and enteric infections. Am J Gastroenterol. 2009;104(suppl 2):S10-S16.
6. Health Protection Agency. Reports of Clostridium difficile isolated from faecal specimens under the voluntary reporting scheme: England, Wales, and Northern Ireland 1990-2004 Available online at htip//www.hpa.org.uk/infections/ topics-az/clostridium-difficile/vol-data.htm.
7. Barrett S. Clostridium difficile - the next step in mandatory reporting. J Hosp Infect. 2004;56:83.
8. Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102:2047-2056. (Pubitemid 47301504)
9. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile - associated diarrhea: a review. Arch Intern Med. 2001;161:525-533. (Pubitemid 32167517)
10. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339-1350. (Pubitemid 36748921)
11. Pepin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004;171:466-472.
12. Dial S, Delaney JA, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989-2995. (Pubitemid 41817660)
13. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Strieker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-1960. (Pubitemid 39411203)
14. Sarkar M, Hennessy S, Yang YX. Proton-pump inhibitor use and the risk for community-acquired pneumonia. Ann Intern Med. 2008;149:391-398.
15. Herzig SJ, Howell MD, Ngo LH, Marcantonio ER. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA. 2009;301:2120-2128.